Telehealth Ketamine for Treatment-Resistant Conditions

"Treatment resistance" is the common thread connecting most patients who come to ketamine therapy. They have tried the standard options, not responded adequately, and are looking for something different. Understanding what treatment resistance means clinically—and which treatment-resistant conditions have the strongest evidence for ketamine—helps patients assess whether they are strong candidates.

Defining Treatment Resistance

Treatment resistance does not mean a condition is untreatable—it means that standard, first-line treatments have not produced adequate relief. The definition is specific to each condition:

Treatment-Resistant Depression (TRD)

The standard clinical definition of TRD is major depressive disorder that has not responded to at least two adequate antidepressant trials. An "adequate trial" generally means:

• The correct drug class for the indication
• At an adequate therapeutic dose
• For an adequate duration (typically 6-8 weeks at therapeutic dose)

Approximately 30% of patients with major depression do not respond to the first antidepressant they try, and 15-30% do not achieve remission despite multiple medication trials—a clinically significant population. For a deep dive into the depression application specifically, see telehealth ketamine for depression.

Treatment-Resistant Anxiety

Treatment-resistant anxiety disorders are less precisely defined than TRD, but generally include patients who have not responded adequately to:

• At least two SSRIs or SNRIs
• An adequate trial of buspirone (for GAD)
• An adequate course of condition-appropriate psychotherapy (CBT, ERP for OCD)

Treatment-Resistant PTSD

PTSD treatment resistance typically means inadequate response to (see our dedicated telehealth ketamine for PTSD guide):

• At least one first-line SSRI or SNRI (sertraline or paroxetine for PTSD)
• An adequate course of evidence-based trauma therapy (PE, CPT, or EMDR)

Refractory Chronic Pain

Chronic pain treatment resistance is defined relative to the specific condition and typically includes failure of:

• Appropriate first-line medications (gabapentinoids, TCAs for neuropathic pain; NSAIDs, opioids for other types)
• Physical therapy and rehabilitation
• Interventional procedures where indicated

Conditions With Strongest Evidence for Telehealth Ketamine

1. Treatment-Resistant Major Depression

This is where the evidence is clearest and most robust. Multiple RCTs, meta-analyses, and the FDA's own approval of esketamine (which established the validity of the mechanism) support ketamine's use in TRD. Telehealth ketamine for TRD is the most established use case.

Best candidate profile:

• 2+ adequate antidepressant trials without remission
• Moderately severe depression (PHQ-9 score 10-19)
• Psychiatrically stable
• Engaged in or willing to engage with psychotherapy
• No significant medical comorbidities

2. PTSD with Inadequate Response to Standard Treatment

The evidence base is growing. Patients with PTSD who have not responded to EMDR, CPT, or first-line SSRIs represent a population with high unmet need and growing evidence for ketamine response.

Best candidate profile:

• Completed course of trauma-focused therapy without adequate response
• Currently working with a trauma-informed therapist
• Not in active traumatic situation
• Able to maintain safety during potentially difficult sessions

3. Treatment-Resistant GAD with Comorbid Depression

Generalized anxiety disorder rarely exists without comorbid depression. Treatment-resistant presentations of this comorbid condition respond well to ketamine's combined anxiolytic and antidepressant mechanisms.

Best candidate profile:

• GAD + MDD not responding to combined antidepressant and therapy
• Willing to engage with integration work addressing both anxiety and mood

4. CRPS and Refractory Neuropathic Pain

For chronic pain applications, CRPS is the best-evidenced condition. Telehealth suitability depends heavily on whether the patient has already established care through IV ketamine and is seeking maintenance at lower doses.

The "Treatment History" Documentation

When applying to telehealth ketamine platforms for treatment-resistant conditions, be prepared to document your treatment history:

• Names of all medications tried, doses, durations, and reasons for discontinuation
• Types of therapy you have tried, duration, and outcomes
• Any hospitalizations or intensive outpatient programs
• Your current treatment team and their contact information

This documentation serves several purposes: it establishes the clinical rationale for ketamine, it helps the provider understand what has and has not worked, and it creates a record that could support insurance reimbursement efforts.

Who May Not Be Treatment-Resistant Enough

An honest conversation: ketamine is not the right first step for most patients. Before pursuing ketamine, patients should typically have:

• Given at least two medications a fair trial
• Engaged with therapy (not just seen a prescriber)
• Addressed modifiable factors (substance use, sleep, exercise) that affect mental health
• Consulted with a psychiatrist if primary care treatments have failed

Patients who seek ketamine without this treatment history may find that standard treatments they have not tried are effective, less expensive, and carry lower long-term risk. Telehealth ketamine is a valuable option for those who have genuinely not responded to standard care—not a first resort.

Maximizing Benefit as a Treatment-Resistant Patient

Patients with treatment-resistant conditions who engage most deeply with ketamine therapy—combining sessions with active psychotherapy, integrating behavioral changes, and working consistently with integration practices—tend to sustain benefit longer than those who treat ketamine as a passive medication. Treatment resistance does not mean the condition cannot change; it often means the change requires more than medication alone, and ketamine can be the catalyst that makes the deeper work possible.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches